Safety and Tolerability of MGD014 and MGD020 With Vorinostat or Treatment Interruption in HIV-1

Phase 1, randomised, open-label trial of MGD014 and MGD020 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Percent of Participants Experiencing At Least One Grade 3 or Greater Adverse Event that are Possibly or Definitely Related to Study Treatment at 14 weeks and Proportion of Participants who Received Full Course of Study Treatment at 12 weeks. Started Oct 2025; status: suspended.